Physician profile
Andrew Rogers
NPI 1972968238
$7,141.18
in general payments reported to CMS, 2019-2025
25 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $478 · 2023: $2,161 · 2024: $2,612 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,373.38 |
| Education | $289.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $589.57 | 2023-2025 | |
| Incyte Corporation | $554.33 | 2022-2025 | Opzelura |
| Pfizer INC. | $546.04 | 2022-2025 | |
| Galderma Laboratories, L.P. | $512.05 | 2023-2025 | Aklief, Oracea, Twyneo |
| Genzyme Corporation | $493.00 | 2022-2025 | |
| Dermavant Sciences, INC. | $459.72 | 2023-2024 | Vtama |
| Leo Pharma INC. | $450.43 | 2022-2025 | Adbry |
| Abbvie INC. | $439.26 | 2023-2025 | Skyrizi, Rinvoq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $437.39 | 2022-2024 | Spevigo |
| Ucb, INC. | $399.48 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $395.53 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $327.39 | 2022-2024 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $300.34 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $237.60 | 2022-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $227.74 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $198.98 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.46 | 2022-2025 | Siliq, Targretin, Duobrii |
| Almirall LLC | $110.23 | 2022-2025 | Klisyri, Seysara |
| Organon LLC | $108.55 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $64.64 | 2022-2023 | |
| Strata Skin Sciences, INC. | $39.79 | 2025 | Xtrac |
| Regeneron Healthcare Solutions, INC. | $28.26 | 2025 | Dupixent |
| Biowound Solutions, INC. | $19.16 | 2025 | Bio-Connekt |
| Botanix Sb INC | $15.23 | 2025 | Sofdra |
| Kerecis Limited | $10.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.